Flurazepam
Dalmane (flurazepam) is a small molecule pharmaceutical. Flurazepam was first approved as Dalmane on 1982-01-01. It is used to treat sleep initiation and maintenance disorders in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flurazepam hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DALMANE | Bausch Health Companies | N-016721 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| flurazepam hydrochloride | ANDA | 2013-06-03 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | 2 | 1 | 4 |
| Vascular ring | D000073872 | Q25.45 | — | — | — | 1 | 1 | 2 | |
| Fluorescein angiography | D005451 | — | — | — | 1 | — | 1 | ||
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | 1 | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | — | 2 | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acoustic neuroma | D009464 | HP_0009588 | — | 1 | — | — | — | 1 | |
| Pulmonary valve stenosis | D011666 | EFO_1001138 | — | 1 | — | — | — | 1 | |
| Ventricular heart septal defects | D006345 | Q21.0 | — | 1 | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | 2 | 3 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 1 | — | — | — | 1 | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | 1 | — | — | — | 1 | 2 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | 1 | — | — | — | — | 1 | ||
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | — | — | — | — | 1 |
| Adenomatous polyps | D018256 | D28 | 1 | — | — | — | — | 1 | |
| Atrial heart septal defects | D006344 | EFO_1000825 | Q21.1 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | — | — | — | — | 1 | |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | — | 1 | 1 | ||
| Choroidal neovascularization | D020256 | — | — | — | — | 1 | 1 | ||
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | 1 | ||
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | — | — | — | 1 | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | — | 1 | 1 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | — | — | 1 | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | — | 1 | 1 | ||
| Nasopharyngeal neoplasms | D009303 | — | — | — | — | 1 | 1 | ||
| Chorioretinitis | D002825 | HP_0012424 | H30 | — | — | — | — | 1 | 1 |
| Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FLURAZEPAM |
| INN | flurazepam |
| Description | Flurazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia. It has a role as a sedative, an anticonvulsant, a GABAA receptor agonist and an anxiolytic drug. It is a 1,4-benzodiazepinone, an organochlorine compound, a member of monofluorobenzenes and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | antianxiety agents (diazepam type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21 |
Identifiers
| PDB | — |
| CAS-ID | 17617-23-1 |
| RxCUI | 4501 |
| ChEMBL ID | CHEMBL968 |
| ChEBI ID | — |
| PubChem CID | 3393 |
| DrugBank | DB00690 |
| UNII ID | IHP475989U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,756 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
783 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more